Related Experiment Videos
Prophylaxis of superficial bladder cancer with instillation of adriamycin or mitomycin C
S Isaka1, T Okano, J Shimazaki
1Department of Urology, School of Medicine, Chiba University, Japan.
Abstract:
A multicenter trial for postoperative prophylaxis of superficial Ta-T1, G1-G2 bladder cancer was performed. Intravesical instillation using either 20-30 mg adriamycin or 20 mg mitomycin C per dose was carried out for 4 weeks or 2 years. Patients without instillation served as controls. A total of 259 patients was considered eligible for the evaluation. The instillation group showed a better disease free survival rate than the control group. Better prophylactic effects of instillation therapy were observed when one of following factors was present: multiple tumors, large tumors, T1 and G2 bladder cancer. The total dose of drug instilled seemed to correlate with the effects, but there were no differences between adriamycin and mitomycin C. The side effects were minimal and temporary.
Insights
Intravesical instillation chemotherapy significantly improved disease-free survival for superficial bladder cancer patients. This treatment was most effective for patients with multiple, large, or advanced-stage (T1, G2) tumors, with minimal side effects.
Area of Science:
- Urology
- Oncology
- Pharmacology
Background:
- Superficial bladder cancer (Ta-T1, G1-G2) requires effective postoperative prophylaxis to prevent recurrence.
- Intravesical chemotherapy is a common treatment modality for non-muscle invasive bladder cancer.
Purpose of the Study:
- To evaluate the efficacy and safety of intravesical adriamycin or mitomycin C for postoperative prophylaxis of superficial bladder cancer.
- To identify patient subgroups that benefit most from intravesical instillation therapy.
Main Methods:
- A multicenter trial involving 259 eligible patients with superficial bladder cancer.
- Patients received intravesical instillation of adriamycin (20-30 mg) or mitomycin C (20 mg) for 4 weeks or 2 years, compared to a control group without instillation.
Main Results:
- The instillation group demonstrated a significantly better disease-free survival rate compared to the control group.
- Prophylactic effects were more pronounced in patients with multiple tumors, large tumors, or those with T1 and G2 stage/grade bladder cancer.
- No significant difference in efficacy was observed between adriamycin and mitomycin C, and total instilled dose correlated with effects.
Conclusions:
- Intravesical chemotherapy is an effective postoperative prophylactic treatment for superficial bladder cancer, enhancing disease-free survival.
- The therapy is particularly beneficial for high-risk patients (multiple, large, T1, G2 tumors).
- Adriamycin and mitomycin C show comparable efficacy with minimal and temporary side effects.